STUDY QUESTION: Does signaling via the cannabinoid (CB 1 ) receptor play a role in the pathogenesis of endometriosis in a mouse model?
Introduction
Endometriosis, a sterile inflammatory disease characterized by growth of endometrial tissue at ectopic locations, is frequently associated with abdominal pain and subfertility (Vercellini et al., 2009) . The definitive cause of the disease remains unknown, although the retrograde menstruation/transplantation hypothesis is the most widely accepted (Sampson, 1927) .
In the peritoneal cavity, menstruating tissue triggers a proinflammatory response that further stimulates activation of the local axon terminals, eventually inducing pain perception (Laux-Biehlmann et al., 2015) . Endometriosis treatment is still an unmet clinical need since an optimal drug that allows for both pain and infertility management does not exist (Giudice, 2010) .
Cannabinoids and modulators of the endocannabinoid system have recently emerged as potential pharmacological targets in endometriosis as they affect specific mechanisms that are critical to establishment of the disease and its maintenance, including inflammation, cell migration, proliferation and survival (Sanchez et al., 2012) . The endocannabinoid system comprises: the bioactive lipid mediators, i.e. the endocannabinoids; the enzymes involved in their synthesis and degradation and the cannabinoid (CB) receptors (De Petrocellis and Di Marzo, 2009 ). One of the most comprehensively studied endocannabinoids is the fatty acid amide, N-arachidonoyl-ethanolamine (anandamide, AEA). The biosynthesis of AEA, which occurs 'on demand' in response to various stimuli, is mainly catalyzed by N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD). Once released in the extracellular space AEA can bind CB 1 , a receptor largely expressed in the central nervous system, but also in the liver, heart, adipose tissue, endometrium and ovary, or CB 2 , mainly expressed in immune cells and in other peripheral tissues. AEA signaling is terminated through catabolism by the endoplasmic reticulumlocalized enzyme fatty acid amide hydrolase (FAAH) .
Activation of CB receptor-associated signaling cascades induces wellcharacterized central psychoactive effects, but it also induces peripheral responses including proliferation, apoptosis, angiogenesis and inflammation (De Petrocellis and Di Marzo, 2009; Maccarrone et al., 2015) .
Historically, the effects of the exogenous cannabinoids on the human female reproductive tract have been extensively studied in marijuana smokers showing that, at high doses, they can alter endometrial decidualization, trophoblast development and invasiveness, oviductal transport, and prostaglandin production by human gestational tissues (Di Blasio et al., 2013) . The mouse and human endometrium emerge as a significant source of endogenous cannabinoids, since levels of AEA are higher in the uterus than in other tissues (Taylor et al., 2010) . In the uterus, CB 1 is more highly expressed in glandular epithelium than in stroma, and its expression is regulated by progesterone (Resuehr et al., 2012) . The expression of CB 2 , NAPE-PLD and FAAH in the uterus has been demonstrated across the menstrual cycle (Scotchie et al., 2015; Sanchez et al., 2016) . CB 1 and CB 2 receptors are present in epithelial and stromal cell lines derived from eutopic endometrium and deep infiltrating endometriotic nodules (Leconte et al., 2010) . In this study, high concentrations of a CB 1 /CB 2 synthetic agonist (WIN-55212-2) reduced in vitro proliferation of human deep infiltrating endometriotic stromal cells, and decreased the volume of the human implants grafted in a nude mouse model. The functional involvement of the CB 1 receptor in endometriosis is suggested by data showing that human endometrial stromal cells stimulated in vitro with methanandamide (MET), a more stable analog of AEA, display an enhanced migratory capacity via activation of the phosphoinositide 3-kinase/Protein kinase B (PI3K/Akt) and extracellular signalregulated kinase (ERK)1/2 pathways (Gentilini et al., 2010) . Since exogenous cannabinoids appear to have a general favorable effect in limiting cell proliferation but they also tend to specifically sustain endometrial cell migration in vitro, more careful and specific studies addressing the role of individual components of the endocannabinoid system are needed. To this end, we have analyzed the specific role of the CB 1 receptor in a well-characterized mouse model of endometriosis.
Materials and Methods
Drugs 17β-Estradiol (E 2 ) and MET were obtained from Tocris Bioscience (Bristol, UK). E 2 was dissolved in dimethylsulfoxide (DMSO) at 20 mg/ml as a stock solution, and diluted in arachis oil just before s.c. injection at a dose of 3 μg/mouse. MET was dissolved in DMSO at 10 mg/ml as a stock solution, and diluted in saline just before i.p. injection at a dose of 5 mg/kg. DMSO diluted in phosphate-buffered saline (PBS) served as the vehicle.
Mouse model of endometriosis
The mouse model of endometriosis was adapted from the model previously described and further validated by our group (Somigliana et al., 1999; Mariani et al., 2012) . In this model, endometriotic lesions with the same histo-morphological and functional features develop in both Balb/c and C57Bl/6 mice. Briefly, 8-week-old female mice (Charles River Laboratories, Calco, Italy) were kept under controlled conditions and allowed to have at least 1 week of acclimation to the environment. One week before surgery, donor mice were injected with E 2 (3 μg/mouse). On Day 0, donor mice were euthanized, the uterus was removed, the two horns were isolated, the myometrium was removed by scraping and the remaining endometrial tissue was reduced to small fragments with scissors. The fragments derived from the isolated uterine horns were weighed and suspended in saline with ampicillin (1 mg/ml). The size of the animal cohort in each experiment is indicated in the corresponding figure legends. In the first set of experiments, endometriosis was induced by i.p. injection of equal amounts of fragmented endometrial tissue from a Balb/c or C57Bl/6 donor mouse into the peritoneum of two Balb/c or C57Bl/6 recipient mice, one of which was treated with MET (5 mg/kg) and the other was treated with vehicle alone, on Days 1-5 and 8-12. In the second experiment, donor endometrial tissue from wild-type (WT) C57Bl/6 or CB 1 −/− C57Bl/6 mice was injected into WT C57Bl/6 or CB 1 −/− C57Bl/6 recipient mice, respectively. In the third experiment, donor endometrial tissue from CB 1 −/− C57Bl/6 was injected into WT C57Bl/6 recipient mice, and, as a control, donor endometrial tissue from WT C57Bl/6 was injected into WT C57Bl/6 recipient mice. In the fourth experiment, donor endometrial tissue from C57Bl/6 WT was injected into C57Bl/6 CB 1 −/− recipient mice, and, as a control, donor endometrial tissue from C57Bl/6 WT was injected into the peritoneum of C57Bl/6 WT recipient mice.
In all experiments, mice were euthanized on Day 14. On Day 14, the lesions were identified as translucid isolated superficial lesions mainly on the abdominal wall and the epiploon, with stromal and glandular components (Supplementary Figure S1) . The lesions were isolated by an operator blinded to the experiment, and measured with a caliper immediately after excision. Although it is somewhat simplistic to imply that lesions are regular ovoids, we used the larger diameter (i) and the smallest diameter (ii) to avoid overestimating the actual volume: the size of each lesion was calculated according to the formula: (4/3)πb 2 A (Ricci et al., 2011; Quattrone et al., 2015) . Based on our previous experience with this model, a cohort of six mice is sufficient to perform a statistical analysis. The choice of the number of animals used is in accordance with the guidelines of the Institutional Animal Care and Use Committee of the IRCCS San Raffaele Hospital and the Italian Ministry of Health. All procedures were performed in the animal facility of the IRCCS San Raffaele Hospital (Milan, Italy) in accordance with European Union and institutional guidelines.
Isolation of total RNA and RT-PCR analysis
Total RNA was isolated using TRI Reagent (Thermo Scientific, Waltham, MA, USA) from one representative ectopic lesion. The aqueous phase was extracted and RNA was precipitated with isopropanol, washed with 70% ethanol before resuspension in water and quantified by NanoDrop (Thermo Scientific, Waltham, MA, USA). Messenger RNA was reversetranscribed using the High Capacity cDNA Reverse Transcript kit (Applied Biosystems, MA, USA). Real-time semi-quantitative PCR amplification was performed with the SYBR PCR Master Mix kit (Applied Biosciences, MA, USA) on a AB7700 Fast Real-Time PCR System with SDS software version 1.4 (Applied Biosystems, MA, USA). All analyses were performed in triplicate and the relative amount of the target was normalized with the housekeeping ribosomal gene 18S. Reactions included 10 μl of 2× SYBR PCR Master Mix (Applied Biosystems, MA, USA), 1 μl of primers to a final concentration of 0.4 μM, 25 ng of template cDNA and nuclease-free water, added to a 96-well reaction plate. The total reaction volume was 20 μl. The cycling conditions were as follows: 10 min at 95°C, 40 cycles of 15 s at 95°C followed by 1 min at 60°C. Melting curves were evaluated for each gene. The data were analyzed by using the comparative Ct method, where Ct is the cycle number at which fluorescence first exceeds the threshold. The Δ cycle threshold (ΔCt) values from each sample were obtained by subtracting the values for the housekeeping gene from the sample Ct. For each experimental sample, the 2 −ΔCt has been calculated and data have been graphically reported as Relative Expression. The 5′−3′ sequences of the primers are the followings: survivin: forward GAGGCTGGCTTC ATCCACTG, reverse CTTTTTGCTTGTTGTTGGTCTCC; N-cadherin: forward AGCGCAGTCTTACCGAAGG, reverse GATATGCGTTGC 
Western blot
Western blot analyses were performed as previously described (Sanchez et al., 2013) . After protein transfer, the membranes were incubated overnight at 4°C with a rabbit anti-mouse CB 1 monoclonal antibody (1:500 in blocking buffer) (Cayman Chemical, Ann Arbor, MI, USA) and an anti-actin monoclonal antibody (1:10 000 in blocking buffer) (Cell Signaling, Beverley, MA, USA). The membranes were washed with PBS 0.5% Tween 20 and incubated for 1 h with a secondary horse-radish peroxidase-conjugated antibody and developed with enhanced chemiluminescence (ECL) luminescent substrate (GE Healthcare Life Sciences, Little Chalfont, UK).
Collection of peritoneal fluid and measurement of IL-6
Peritoneal lavage was performed upon infusion of 500 μl saline into the peritoneal cavity of the mice. The fluid was removed and centrifuged at 1000g to remove cells and debris. The total protein content in peritoneal fluid samples was determined with the Bio-Rad protein assay (Bio-RAD, Hercules, CA, USA) according to the Bradford method. Concentrations of IL-6 were measured by a mouse IL-6 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA).
Statistical analysis
Statistical analysis was performed using a two-tailed unpaired Student's t-test or ANOVA test with Bonferroni post-hoc test as appropriate. P-values of 0.05 or less were considered significant. Statistics were generated using the GraphPad Prism 6.0 (GraphPad Software, Inc., CA, USA).
Results

MET induces an increase in the volume of ectopic endometrial lesions
Endometriosis was induced by injection of endometrial fragments from a donor mouse into the peritoneal cavity of two recipient mice. One mouse of the pair was treated with PBS while the other received MET 5 mg/kg (Fig. 1A) . We confirmed CB 1 receptor protein expression in eutopic endometrium and peritoneal tissue of donor C57Bl/6 mice, as well as in eutopic endometrium, peritoneal tissue and ectopic lesions of both MET-treated and PBS-treated C57Bl/6 recipients (Fig. 1B) . In these mice, the total volume of the lesions of MET-treated mice (mean ± SEM 0.469 ± 0.129 cm 3 ) was higher compared with vehicletreated mice (0.166 ± 0.027 cm 3 ) (Fig. 1C) , with no significant difference in the total number of lesions (1.00 ± 0.26) in PBS-treated mice compared with 1.66 ± 0.33 in MET-treated mice (Fig. 1D) . Similar results were obtained when endometriosis was induced in Balb/c mice. The total lesion volume of MET-treated (0.503 ± 0.126 cm 3 ) was higher compared with vehicle-treated Balb/c mice (0.154 ± 0.040 cm 3 ) (Fig. 1E) , with no change in the total number of lesions (1.75 ± 0.28 in PBS-treated mice compared with 1.85 ± 0.26 in MET-treated mice) (Fig. 1F ). 
MET treatment affects the expression profile of genes involved in cell adhesion and inflammation
In order to elucidate the mechanisms by which MET regulates the ectopic implantation of endometrial cells, we studied the expression of some of the genes that are involved in cell-cell adhesion and cellextracellular matrix adhesion. We found a significant upregulation of the expression of survivin (P = 0.03), N-cadherin (P = 0.02) and integrin β1 (P = 0.02) mRNA in the lesions of MET-treated Balb/c mice compared with the lesions of vehicle-treated mice. No significant differences in E-cadherin expression were observed between the two groups ( Fig. 2A) .
We then assessed the effect of MET on the local immune response and we found that levels of IL-6 transcripts were higher in the lesions of MET-treated (2.83 ± 1.16) compared with the lesions of vehicletreated (0.55 ± 0.28) Balb/c mice (Fig. 2B, left panel) . In representative mice with endometriosis, the levels of total IL-6 protein in the peritoneal fluid were increased upon MET treatment compared with vehicle (16.70 ± 2.22 versus 11.53 ± 1.45 ng/mg of total protein) although the difference was not statistically significant (Fig. 2B, right  panel) . MET treatment also increased IL-6 protein levels in the integrin β1 mRNA expression in ectopic endometrial tissue from MET-treated (n = 9) compared with control (n = 9) Balb/c mice. mRNA data obtained by RT-PCR were normalized relative to 18S rRNA. (B) Left panel: IL-6 mRNA expression in ectopic endometrium tissue from MET-treated mice (n = 9) and control mice (n = 9) (left panel). mRNA data were normalized relative to 18S rRNA. Data are presented as mean ± SEM. Right panel: IL-6 protein levels (ng protein levels normalized by mg of total protein content) in the peritoneal fluid of PBS-treated (n = 3) and MET-treated mice (n = 3) with no endometriosis, and PBS-treated (n = 4) and MET-treated (n = 4) mice with endometriosis. All data are expressed as mean ± SEM. Statistical analysis was performed using two-tailed unpaired Student's t test (mRNA expression) or ANOVA test with Bonferroni post-hoc test (IL-6 protein levels). *P < 0.05 versus control.
peritoneal fluid of mice with no endometriosis compared with vehicle (11.35 ± 0.56 versus 2.51 ± 0.51 ng/mg of total protein). Transcript levels of TNFα, IL-1β and IL-1α in the lesions of MET-treated mice were comparable to those of vehicle-treated mice (data not shown).
Expression of CB 1 in both endometrial cells and the peritoneal microenvironment is required for the development of ectopic lesions MET preferentially mediates its effects via binding to CB 1 (Pertwee et al., 2010) . In order to examine whether MET-induced ectopic lesion development is mediated by CB 1 independent of the type and concentration of a specific ligand, experimental endometriosis was induced by transfer of syngeneic endometrial tissue either in CB 1 −/− C57Bl/6 mice or in their WT littermates (Fig. 3A) . After 14 days, the total volume of the lesions isolated from CB 1 −/− mice was significantly lower (Fig. 3B) . Levels of IL-6 transcripts were similar in CB 1 −/− and WT mice (data not shown).
To verify whether the expression of CB 1 by donor endometrial tissue contributed to endometriosis development, we performed an experiment in which recipient WT mice were injected with endometrium from either WT or CB 1 −/− donor mice (Fig. 4A) endometrium from WT donors) (1.7 ± 0.33). Furthermore, we found a reduced expression of survivin mRNA in the ectopic lesions of WT mice injected with endometrium of CB 1 −/− mice compared with the lesions of WT mice injected with endometrium from WT mice (Fig. 4B) . N-cadherin transcript expression was not significantly different in the two groups. Levels of IL-6 transcripts were similar in the two groups of recipient mice (data not shown).
To analyze the contribution of CB 1 expression in the recipient peritoneal environment to endometriosis development, we performed an experiment in which recipient CB 1 −/− mice or WT mice were injected with endometrium from WT mice (Fig. 5A) . Two out of six CB 1 −/− mice that received endometrial fragments from WT donors did not develop any detectable lesion, and in the other four mice the total lesion volume was significantly reduced (0.078 ± 0.037 cm 3 ) compared with the control group (WT mice that received endometrial fragments from WT donors) (0.369 ± 0.06 cm 3
). The total lesion number was significantly reduced in CB 1 −/− mice that received endometrial fragments from WT donors (0.8 ± 0.3) compared with the control group (WT mice that received endometrial fragments from WT donors) (2 ± 0.36). Furthermore, expression of survivin and N-cadherin mRNA was significantly reduced in the ectopic lesions of the CB 1 −/− mice injected with endometrium of WT mice compared with the control group (Fig. 5B) . Levels of IL-6 transcripts were similar in the two groups of recipient mice (data not shown). These data support the hypothesis that signaling via CB 1 in both endometrial cells and in cells present in the peritoneal microenvironment contributes to the development of ectopic endometrial lesions.
Discussion
In this study, we present evidence that signaling via the CB 1 receptor affects the establishment and development of endometriosis in immune-competent mice. Two findings support this view. First, mice treated with a (predominantly) CB 1 agonist develop larger ectopic lesions. Second, less severe lesions developed upon endometriosis Statistical analysis was performed using two-tailed unpaired Student's t-test. *P < 0.05 versus control.
induction in the absence of functional CB 1 expression either in endometrial cells or in the cells of the peritoneal microenvironment. Our results are in apparent contrast with those obtained in a model of human endometriotic tissue transplanted into nude mice, which showed a reduced implant volume upon treatment with the nonselective CB 1 /CB 2 agonist WIN-55212-2 (Leconte et al., 2010) . One likely explanation for the differing findings might be the inherent differences between the mouse and the human endometrium, although they do share comparable histological features at corresponding cycle stages (Greaves et al., 2014) . Another possibility for this discordancy can be explained by the use, in our study, of the mainly CB 1 receptor selective agonist MET (K i values are 61-543 nM for CB 1 and 279-1940 nM for CB 2 ), versus the use of the less selective agonist WIN-55212-2 (K i values are 1.89-123 nM for CB 1 and 0.28-16.2 nM for CB 2 ) in the study by Leconte et al. (2010) (Pertwee et al., 2010) . In addition, our model is designed to evaluate the development of the disease in its initial stage, which is characterized by endometrial cell proliferation, invasion of adjacent tissues, defective apoptosis, neoangiogenesis and sustained inflammation.
The transplant model used in the Leconte et al. (2010) study is instead aimed at evaluating the fate of already established lesions, where the observed effects might be mainly mediated by anti-fibrotic and/or anti-angiogenic mechanisms.
Interestingly, MET has been shown to enhance the migration of primary endometrial cells via the CB 1 receptor through the activation of PI3K/Akt and ERK1/2 pathways that control cellular proliferation and survival (Gentilini et al., 2010) . These findings support an important role of signaling through the CB 1 receptor to regulate cell invasiveness, proliferation and resistance to apoptosis typical of endometriosis. It cannot be excluded that migration of endometrial cells could also be regulated via non-CB 1 receptors, such as CB 2 , or G Protein-Coupled Receptor 18 (GPR18), as was previously demonstrated using the endometrial epithelial cell line HEC-1B (McHugh et al., 2012) .
Here, we report that MET favors survival of the endometriotic tissue in association with an increased mRNA level of the cell adhesionrelated molecules N-cadherin and integrin β1. An elevated expression of N-cadherin was already observed in both human epithelial and stromal cells of endometriotic lesions when compared with eutopic rRNA. Mean ± SEM is reported. Statistical analysis was performed using two-tailed unpaired Student's t-test. *P < 0.05 versus control.
endometrium but its physiological role has not been clarified yet (Bartley et al., 2014) . The role of endocannabinoids in the modulation of N-cadherin activity has also been demonstrated in the neuronal system where they promote axonal growth, and CB 1 antagonists inhibit the N-cadherin component of the neurite outgrowth response (Williams et al., 2003) . Cannabinoids have been predominantly characterized as antiinflammatory but immune effects can vary with concentration, type or magnitude of stimulus (Karmaus et al., 2013) . CB 1 antagonists have been shown to suppress the release of pro-inflammatory cytokines in vitro (Sugamura et al., 2009) , and in vivo (Mnich et al., 2010) . As an active immune response characterized by elevated IL-6 levels is essential for the initiation and development of endometriosis (Bacci et al., 2009; Mariani et al., 2012; Kang, et al., 2014) , inflammation represents a relevant pharmacological target. Here, we showed that the more severe disease in MET-treated mice is associated with both an increase of IL-6 mRNA in ectopic lesions and higher levels of IL-6 protein in the peritoneal fluid. However, these higher IL-6 protein levels are in part a consequence of MET treatment, since MET increases IL-6 protein levels also in mice without endometriosis. Lack of CB 1 expression did not affect the peritoneal inflammatory state, as IL-6 levels in the ectopic lesions of CB 1 −/− mice were similar to those detected in their WT littermates (data not shown). This suggests that the inflammation observed in MET-treated mice with endometriosis could be the consequence of a more severe peritoneal homeostasis disruption rather than being a direct effect of CB 1 activation by MET. Several differences exist between the eutopic endometrium of women with and without endometriosis as well as between ectopic and autologous eutopic endometrium of endometriosis patients (Novembri et al., 2011) . Furthermore, there is increasing evidence that the phenotype of the pelvic peritoneal mesothelium may contribute to the development and progression of peritoneal endometriosis (Young et al., 2013) . Here, we demonstrate that expression of CB 1 on endometrial cells, on peritoneal mesothelial cells, or on cells present in the inflammatory peritoneal environment might also contribute to ectopic lesion development. Together, these data support the hypothesis that a deregulation of the endocannabinoid system leading to aberrant cannabinoid signaling via the CB 1 receptor may impact development of endometriosis.
High expression of CB 1 on somata and fibers of both the sensory and sympathetic neurons that innervate peritoneal endometriosis lesions was observed in a rat model of surgically induced endometriosis. Interestingly, a CB 1 receptor agonist has been shown to reduce endometriosis hyperalgesia in a rat model (Dmitrieva et al., 2010) . On the basis of these data and of our results showing development of larger lesions in a mouse model upon treatment with a CB 1 receptor agonist, the combined effect on the activation of sensory and sympathetic fibers within the lesion on the proliferation of endometriotic cells, as well as the effect on the general uterine function, must be carefully evaluated for the future development of medical treatments aimed at regulating CB 1 activation. Our recent work showing that endocannabinoid and endocannabinoid-related signaling (via CB 1 , CB 2 and transient receptor potential vanilloid type-1) is altered in women with endometriosis (Sanchez et al., 2016) provides further momentum for investigation of the pharmacotherapy for this disease.
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